Healthcare Business Recap: Apricus LICENSES Takeda, Cornerstone’s Med Rejected By FDA

Shares of Apricus Biosciences, Inc. (NASDAQ:APRI) jump on the news that it has licensed Takeda Pharmaceuticals (TKPHF.PK)(TKPYY.PK) to market Vitaros, its erectile dysfunction medication in the United Kingdom. Takeda will pay Apricus an upfront payment along with milestone payments of as much as €35 million.

Don’t Miss: Citigroup Takes Note of Apple’s iPad Success.

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) shares plummet after the firm priced its offering of 8 million units at $4 each, marking a 12 percent discount to Wednesday’s close. Each unit contains one share of common stock and a warrant to purchase 0.35 of a share.

Shares of Cornerstone Therapeutics Inc. (NASDAQ:CRTX) tumble following an FDA advisory panel rejecting approval of lixivaptan for the treatment of low sodium levels in the blood associated with heart failure. The shares resumed trading at 2:00 subsequent to a halt at the open.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>